- Home
- EARN vs ATOS Comparison
EARN vs ATOS Comparison
Compare EARN & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EARN
- ATOS
- Stock Information
- Founded
- EARN 2012
- ATOS 2009
- Country
- EARN United States
- ATOS United States
- Employees
- EARN N/A
- ATOS N/A
- Industry
- EARN Real Estate Investment Trusts
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- EARN Real Estate
- ATOS Health Care
- Exchange
- EARN Nasdaq
- ATOS Nasdaq
- Market Cap
- EARN 164.4M
- ATOS 174.8M
- IPO Year
- EARN 2013
- ATOS 2012
- Fundamental
- Price
- EARN $6.46
- ATOS $1.28
- Analyst Decision
- EARN Hold
- ATOS Strong Buy
- Analyst Count
- EARN 2
- ATOS 3
- Target Price
- EARN $6.00
- ATOS $6.75
- AVG Volume (30 Days)
- EARN 485.8K
- ATOS 658.8K
- Earning Date
- EARN 11-12-2024
- ATOS 11-12-2024
- Dividend Yield
- EARN 14.86%
- ATOS N/A
- EPS Growth
- EARN 275.17
- ATOS N/A
- EPS
- EARN 1.02
- ATOS N/A
- Revenue
- EARN N/A
- ATOS N/A
- Revenue This Year
- EARN N/A
- ATOS N/A
- Revenue Next Year
- EARN $51.17
- ATOS N/A
- P/E Ratio
- EARN $6.36
- ATOS N/A
- Revenue Growth
- EARN N/A
- ATOS N/A
- 52 Week Low
- EARN $5.54
- ATOS $0.65
- 52 Week High
- EARN $7.26
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- EARN 42.16
- ATOS 37.45
- Support Level
- EARN $6.26
- ATOS $1.36
- Resistance Level
- EARN $6.68
- ATOS $1.66
- Average True Range (ATR)
- EARN 0.17
- ATOS 0.08
- MACD
- EARN -0.01
- ATOS -0.02
- Stochastic Oscillator
- EARN 35.59
- ATOS 0.00
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.